Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localization

Doxorubicin pathways

(2010) Caroline F. Thorn et al.   Pharmacogenetics and Genomics

Kinetic studies of AKR1B10, human aldose reductase-like protein: Endogenous substrates and inhibition by steroids

(2009) Satoshi Endo et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments

(2009) S. A. Bustin et al.   CLINICAL CHEMISTRY

Induction of 1C aldoketoreductases and other drug dose-dependent genes upon acquisition of anthracycline resistance

(2009) Zachary W. Veitch et al.   Pharmacogenetics and Genomics

Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance

(2008) Stacey L Hembruff et al.   BMC CANCER

Reduction of doxorubicin and oracin and induction of carbonyl reductase in human breast carcinoma MCF-7 cells

(2008) Martina Gavelová et al.   CHEMICO-BIOLOGICAL INTERACTIONS

Role of human aldo–keto-reductase AKR1B10 in the protection against toxic aldehydes

(2008) Hans-Jörg Martin et al.   CHEMICO-BIOLOGICAL INTERACTIONS

Carbonyl Reductase 1 Is a Predominant Doxorubicin Reductase in the Human Liver

(2008) N. Kassner et al.   DRUG METABOLISM AND DISPOSITION

Inactivation of the anticancer drugs doxorubicin and oracin by aldo–keto reductase (AKR) 1C3

(2008) Romana Novotna et al.   TOXICOLOGY LETTERS